Here is the design of a clinical trial:

Official Title: Assessment of Precision Irradiation in Early NSCLC and Interstitial Lung Disease (ASPIRE-ILD): A Phase II Trial

Included conditions:
- Non Small Cell Lung Cancer
- Interstitial Lung Disease

Study Armgroups:
- {'label': 'Treatment Arm: Stereotactic Ablative Radiotherapy', 'type': 'EXPERIMENTAL', 'description': 'Stereotactic ablative radiotherapy for early non-small cell lung cancer and interstitial lung disease', 'interventionNames': ['Radiation: Stereotactic Ablative Radiotherapy']}

Interventions:
- {'type': 'RADIATION', 'name': 'Stereotactic Ablative Radiotherapy', 'description': 'Stereotactic ablative radiotherapy for early non-small cell lung cancer and interstitial lung disease', 'armGroupLabels': ['Treatment Arm: Stereotactic Ablative Radiotherapy']}

Primary Outcomes:
- {'measure': 'Overall Survival', 'description': 'Time from enrollment to death from any cause', 'timeFrame': '4 years'}

Please estimate the sample size based on the assumption: 
The study uses a one-sample, one-sided binomial test at the 0.05 significance level, with >80% power and assumes a 10% dropout or loss to follow-up rate before one year.
Statistical design and sample size
        The primary endpoint of this study is overall survival in patients able to be treated with a dose of 50âGy in 5 fractions, with a comparison to historical controls of untreated medically inoperable patients stage I NSCLC, which consistently have survivals of less than 1âyear, as described in the Background section. Demonstration in this study that median OS after SABR is statistically greater than a historical control of <â12âmonths would indicate that SABR is worthwhile in this population of ILD patients, if toxicity is within acceptable limits.
        A sample size of 39 patients provides >80% power to detect an OS improvement of >20% at 1âyear, compared to a historical control of <50% (i.e. 70% vs. 49%), using a one-sample, one sided binomial test at the 0.05 significance level, assuming 10% dropout or loss to follow-up before one year. All cohorts will be combined for this primary analysis.
        SABR will be considered worthwhile if OS is >â1âyear, the risk of grade 3 or 4 pulmonary toxicity is <â35%, and the risk of treatment-related mortality is <â15%.